ArticleWorld journal of gastroenterology2025
Serum C-X-C motif chemokine ligand 9, interleukin 8, and interleukin 22 as key biomarkers in pediatric inflammatory bowel disease.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in non-invasive biomarkers for pediatric inflammatory bowel disease diagnosis.World journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of inflammatory bowel disease (IBD) involves clinical, endoscopic, and radiologic evaluation. Endoscopic procedures, particularly in pediatrics, require general anesthesia and carry potential risks.
aimTo investigate whether serum biomarkers can differentiate between pediatric patients with and without IBD. Secondary objectives included identifying biomarkers that distinguish Crohn's disease (CD) from ulcerative colitis (UC) and assessing their predictive value for progression to biologic therapy.
methodsPediatric patients undergoing diagnostic colonoscopy at British Columbia Children's Hospital between December 2017 and June 2022 were enrolled. Blood samples were collected at colonoscopy, and demographic clinical data, laboratory, and histopathologic evaluation were obtained. An exploratory screen of 50 biomarkers was undertaken in a subset of patients (54 IBD, 41 controls) using Legendplex
resultsThe study included 246 pediatric patients, who had a median age of 13.03 years and were 37.4% female (103 CD, 52 UC, 91 controls). In univariate analyses, C-X-C motif chemokine ligand 9 (CXCL9) was the only biomarker significantly elevated in IBD
conclusionSerum biomarkers, particularly CXCL9, IL-8, and IL-22, can aid in the diagnosis of pediatric IBD. CXCL9 and IL18 were found to be significant predictors of CD, and CXCL1 differed between patients requiring biologic therapy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.